Synthesis, molecular modeling of novel 1,2,4-triazole derivatives with potential antimicrobial and antiviral activities

Acta Pharmaceutica Sciencia

Volumn 52, Issue 3, 2010, Pages 353-364

  El Feky, Sherin M ^a   Abou Zeid, Laila A ^a   Massoud, Mohamed A ^a   Shokralla, Shady G ^a   Eisa, Hassan M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Antibacterial; Antifungal; Catalytic triad recognition; Lipophilicity; Molecular modeling; Triazoles

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 [3 (2 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YL THIO]ACETIC ACID ETHYL ESTER; 2 [3 (2 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]ACETOHYDRAZIDE; 2 [3 (3 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YL THIO]ACETIC ACID ETHYL ESTER; 2 [3 (3 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]ACETOHYDRAZIDE; 2 [3 (3 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YL THIO]ACETIC ACID ETHYL ESTER; 2 [3 (3 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]ACETOHYDRAZIDE; 2 [3 (4 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YL THIO]ACETIC ACID ETHYL ESTER; 2 [3 (4 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO] N' (4 FLUOROBENZYLIDENE) ACETOHYDRAZIDE; 2 [3 (4 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]ACETOHYDRAZIDE; 2 [3 (4 FLUOROBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YL THIO]ACETIC ACID ETHYL ESTER; 2 [3 (4 FLUOROBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]ACETOHYDRAZIDE; 2 [3 (HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO] N' (4 FLUOROBENZYLIDENE) ACETOHYDRAZIDE; 3 [[3 (4 FLUOROBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1 (4 4 TOLYLPIPERAZIN 1 YL) METHYL 1H [1,2,4] TRIAZOLE 5(4H) THIONE; 3 [[3 (4 FLUOROBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1 (4 PHENYLPIPERAZIN 1 YL) METHYL 1H [1,2,4] TRIAZOLE 5(4H) THIONE; 5 [[3 (2 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1H 1,2,4 TRIAZOLE 5(4H) THIONE; 5 [[3 (3 HYDROXYBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1H 1,2,4 TRIAZOLE 5(4H) THIONE; 5 [[3 (4 BROMOBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1H 1,2,4 TRIAZOLE 5(4H) THIONE; 5 [[3 (4 FLUOROBENZYLIDENEAMINO) 1H [1,2,4] TRIAZOL 5 YLTHIO]METHYL] 4 (4 FLUOROPHENYL) 1H 1,2,4 TRIAZOLE 5(4H) THIONE; 5 [[5 (BENZYLTHIO) 4 (4 FLUOROPHENYL) 4H [1,2,4] TRIAZOL 3 YL]METHYLTHIO] N (4 FLUOROBENZYLIDENE) 1H [1,2,4] TRIAZOL 3 AMINE; 5 [[5 (ETHYLTHIO) 4 (4 FLUOROPHENYL) 4H [1,2,4] TRIAZOL 3 YL]METHYLTHIO] N (4 FLUOROBENZYLIDENE) 1H [1,2,4] TRIAZOL 3 AMINE; AMPICILLIN; CLOTRIMAZOLE; ENZYME; FLUCONAZOLE; PROTEIN 1EA1; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISK DIFFUSION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ESCHERICHIA COLI; IN VITRO STUDY; LIPOPHILICITY; MICROMYCETE; MOLECULAR DOCKING; MOLECULAR MODEL; MOLECULAR RECOGNITION; NONHUMAN; STAPHYLOCOCCUS AUREUS;

EID: 79751501264     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Aufort, M., Herscovici, J., Bouhours, P., Moreau, N. and Girard, C. (2008). Synthesis and antibiotic activity of a small molecules library of 1,2,3-triazole derivatives. Bioorg. Med. Chem. Lett. 18: 1195-1198.
2. Barker, K.S. and Rogers, P.D. (2006). Recent insights into the mechanisms of antifungal resistance. Curr. Infect. Dis. Rep. 8: 449-456.
3. Chohan, Z.H., Pervez, H., Rauf, A., Khan, K.M., Maharvi, G.M. and Supuran, C.T. (2004). Antibacterial and antifugal mono- and di-substituted symmetrical and unsymmetrical triazine-derived Schiff-bases and their transition metal complexes. J. Enzyme Inhib. Med. Chem. 19: 161-168.
4. Cordonnier, C., Mohty, M., Faucher, C., Pautas, C., Robin, M. Vey, N., Monchecourt, F., Mahi, L. and Ribaud, P. (2008). Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: Prophysome Study. Int. J. Antimicrob. Agents 31: 135-141.
5. Cowen, L.E. and Lindquist, S. (2005). Fungal evolution, drug resistance, and infectious disease. Science 309: 2185-2189.
6. Herbrecht, R. (2006). Managing the challenges of invasive fungal infections. Int. J. Antimicrob. Agents 1: 1-2.
7. Hyperchem: Molecular Modeling System, Release 6. (1999) Hypercube Inc., Florida
8. Liu, P., Zhu, S., Li, P., Xie, W., Jin, Y., Sun, Q., Wu, Q., Sun, P., Zhang, Y., Yang, X., Jiang, Y. and Zhang, D. (2008). Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents. Bioorg. Med. Chem. Lett. 18: 3261-3265.
9. Liu, Z., Yang, G. and Qing, X. (2001). Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. J. Chem. Technol. Biotechnol. 76: 1154-1158.
10. Mai, A., Rotili, D., Massa, S., Brosch, G., Simonetti, G., Passariello, C. and Palamarai, A.T. (2007). Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg. Med. Chem. Lett. 17: 1221-1225.
11. Metcalf, S.C. and Dockrell, D.H. (2007). Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J. Infect. 55: 287-299.
12. Moelgro molecular viewer MMV 2008.
13. Podust, L., Poulos, T.L. and Waterman, M.R. (2001). Crystal structure of cytochrome P450 14 -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc. Natl. Acad. Sci. USA. 98: 3068-3073.
14. Redding, S.W., Kirkpatrick, W.R., Saville, S., Coco, B.J., White, W., Fothergill, A., Rinaldi, M., Eng, T., Patterson, T.F. and Lopez- Ribot, J. (2003). Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41: 619-622.
15. Ship, J.A., Vissink, A. and Challacombe, S.J. (2007). Use of prophylactic antifungals in the immunocompromised host. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103: 1-14.
16. Sztanke, K., Tuzimski, T., Rzymowska, J., Pasternak, K. and Kandefer-Szersze ZM. (2008). Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur. J. Med. Chem. 43: 404-419.
17. Tatsumi, Y., Yokoo, M., Arika, T. and Yamaguchi, H. (2001). In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob. Agents Chemother. 45: 1493-1499.
18. Varanasi, N.L., Baskaran, I., Alangaden, G.J., Chandrasekar, P.H. and Manavathu, E.K. (2004). Novel effect of voriconazole on conidiation of Aspergillus species. Int. J. Antimicrob. Agents 23: 72-79.
19. Xu, J., Onyewu, C., Yoell, H.J., Ali, R.Y., Vilgalys, R.J. and Mitchell, T.G. (2001). Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 420-427.
20. Yang, J.L., Qu, X.J., Yu, Y., Kohn, E.C. and Friedlander, M.L. (2008). Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int. J. Cancer 123: 258-63